p.82 抽出テキスト
15 Evidence tables Evidence tables are available at European Heart Journal online. 16 Data availability statement No new data were generated or analysed in support of this research. 17 Author information Author/task force Member Affiliations: Cian P. McCarthy, Cardiovascular Division Massachusetts General Hospital and Harvard Medical School Boston, MA, United States of America; Rosa Maria Bruno, PARCC, Université Paris Cité, Inserm, Paris, France, and Pharmacology & Hypertension, AP-HP, Hôpital Européen Georges Pompidou, Paris, France; Sofie Brouwers, Cardiovascular Center Aalst, Department of Cardiology, OLV Clinic Aalst, Aalst, Belgium, and Department of Experimental Pharmacology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium; Michelle D. Canavan, School of Medicine, College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland, and Department of Geriatric Medicine, University Hospital Galway, Saolta Hospitals Group, Galway, Ireland; Claudio Ceconi, Motusmed Clinic, Brescia, Italy; Ruxandra Maria Christodorescu, Department V Internal Medicine, University of Medicine and Pharmacy V Babes, Timisoara, Romania, and Research Center, Institute of Cardiovascular Diseases, Timisoara, Romania; Stella S. Daskalopoulou, Medicine Research Institute of the McGill University Health Centre, McGill University, Montreal, Canada; Charles J. Ferro, Department of Renal Medicine, University Hospitals Birmingham, Birmingham, United Kingdom, and Institute of Cardiovascular Sciences University of Birmingham, Birmingham, United Kingdom; Eva Gerdts, Department of Clinical Science, University of Bergen, Bergen, Norway, and Department of Heart Disease, Haukeland University Hospital, Bergen, Norway; Henner Hanssen, Department Sport, Exercise and Health, Medical Faculty, University of Basel, Basel, Switzerland; Julie Harris (United Kingdom), ESC Patient Forum, Sophia Antipolis, France; Lucas Lauder, Department of cardiology, University hospital Basel, Basel, Switzerland, and Department of internal medicine III, Cardiology, Angiology, and Intensive Care Medicine, Saarland university medical center, Homburg, Germany; Richard J. McManus, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Gerard J. Molloy, School of Psychology, University of Galway, Galway, Ireland; Kazem Rahimi, Deep Medicine, Nuffield Department of Women’s and Reproductive Health, University of Oxford, Oxford, United Kingdom; Vera Regitz-Zagrosek, Charite, University Medicine Berlin, Gender in Medicine, Berlin, Germany; Gian Paolo Rossi, Department of Medicine, DIMED, University of Padua, Padua, Italy; Else Charlotte Sandset, Department of Neurology, Oslo University Hospital, Oslo, Norway, The Norwegian Air Ambulance Foundation, Oslo, Norway, and Institute of Clinical Medicine University of Oslo, Oslo, Norway; Bart Scheenaerts (Belgium), ESC Patient Forum, Sophia Antipolis, France; Jan A. Staessen, Non-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium, and Biomedical Research Group, Faculty of Medicine, University of Leuven, Leuven, Belgium; Izabella Uchmanowicz, Department of Nursing and Obstetrics, Faculty of Health Sciences, Wroclaw Medical University, Wroclaw, Poland; and Maurizio Volterrani, Exercise Science and Medicine San Raffaele Open University, Rome, Italy, and Cardiopulmonary Department, IRCCS San Raffaele, Rome, Italy. 18 Appendix ESC Scientific Document Group Includes Document Reviewers and ESC National Cardiac Societies. Document Reviewers: Ana Abreu (CPG Review Co-ordinator) (Portugal), Michael Hecht Olsen (CPG Review Co-ordinator) (Denmark), Marco Ambrosetti (Italy), Emmanuel Androulakis (United Kingdom), Lia Evi Bang (Denmark), Jesper Nørgaard Bech (Denmark), Michael A. Borger (Germany), Pierre Boutouyrie (France), Luís Bronze (Portugal), Sergio Buccheri (Sweden), Regina Dalmau (Spain), Maria Carmen De Pablo Zarzosa (Spain), Christian Delles (United Severe hypertension in pregnancy and pre-eclampsia In pre-eclampsia or eclampsia with hypertensive crisis, drug treatment with i.v. labetalol or nicardipine and magnesium is recommended. I C In pre-eclampsia or eclampsia associated with pulmonary oedema, nitroglycerin given as an i.v. infusion is recommended. I C In severe hypertension in pregnancy: • drug treatment with i.v. labetalol, oral methyldopa, or oral nifedipine is recommended. Intravenous hydralazine is a second-line option. I C 11 Patient-centred care in hypertension An informed discussion about CVD risk and treatment benefits tailored to the needs of a patient is recommended as part of hypertension management. I C Home BP measurement for managing hypertension by using self-monitored BP is recommended to achieve better BP control. I B Self-measurement, when properly performed, is recommended due to positive effects on the acceptance of a diagnosis of hypertension, patient empowerment, and adherence to treatment. I C Multidisciplinary approaches in the management of patients with elevated BP and hypertension, including appropriate and safe task-shifting away from physicians are recommended to improve BP control. I A © ESC 2024 ABPM, ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme; ACR, albumin:creatinine ratio; AF, atrial fibrillation; ALARA, as low as reasonably achievable; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; CVD, cardiovascular disease; DASH, Dietary Approaches to Stop Hypertension; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; ESC, European Society of Cardiology; HBPM, home blood pressure monitoring; HFpEF, heart failure with preserved ejection fraction; HF(m)rEF, heart failure with (mildly) reduced ejection fraction; HMOD, hypertension-mediated organ damage; i.v., intravenous; MRA, mineralocorticoid receptor antagonist; RAS, renin–angiotensin system; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2-Older Persons; SGLT2, sodium–glucose co-transporter 2; TIA, transient ischaemic attack. ESC Guidelines 3993 Downloaded from academic.oup.com/eurheartj/article/45/38/3912/7741010 by guest on 07 October 2026